Boehringer Ingelheim Pharmaceuticals, Inc. Sustainability Profile
Boehringer Ingelheim Pharmaceuticals, Inc., a leading global player in the pharmaceutical industry, is headquartered in the United States. Founded in 1885, the company has established a strong presence in major operational regions, including Europe, Asia, and Latin America. Specialising in human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing, Boehringer Ingelheim is renowned for its innovative therapies and commitment to research and development. The company’s core products encompass a range of prescription medications, particularly in the fields of respiratory diseases, cardiovascular health, and oncology. Boehringer Ingelheim's unique approach to drug development and patient care has positioned it as a trusted name in the industry, with notable achievements in advancing treatment options and improving patient outcomes. With a focus on sustainability and social responsibility, Boehringer Ingelheim continues to make significant strides in enhancing global health.
DitchCarbon Score
How does Boehringer Ingelheim Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boehringer Ingelheim Pharmaceuticals, Inc.'s score of 26 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Boehringer Ingelheim Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of C.H. Boehringer Sohn AG & Co. KG, which may influence its climate commitments and emissions reporting. As of now, there are no documented reduction targets or climate pledges from Boehringer Ingelheim Pharmaceuticals, Inc. This lack of specific initiatives suggests that the company may still be in the process of developing its climate strategy or reporting framework. Given the absence of direct emissions data and reduction initiatives, it is essential to consider the broader context of the pharmaceutical industry, which is increasingly focusing on sustainability and carbon neutrality. Companies within this sector are often encouraged to adopt science-based targets and participate in initiatives such as the Science Based Targets initiative (SBTi) to align with global climate goals. In summary, while Boehringer Ingelheim Pharmaceuticals, Inc. does not currently report specific emissions or reduction targets, its affiliation with C.H. Boehringer Sohn AG & Co. KG may play a role in shaping its future climate commitments.
How Carbon Intensive is Boehringer Ingelheim Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Boehringer Ingelheim Pharmaceuticals, Inc.'s Location?
Boehringer Ingelheim Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Boehringer Ingelheim Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
